Abstract
The success of platinum-based anticancer drugs, in recent decades, has led to the development of other metallodrugs, which have been driven by the increased platinum resistance and its serious side effects associated with chemotherapy. In particular, the organometallic compounds of rhenium(I), fac-[Re(CO)3(NN)(L)]0/+, which are rapidly and efficiently up taken, with similar or superior ac…